ArthroCare
This article was originally published in The Gray Sheet
Executive Summary
Proposed secondary offering of 1 mil. common stock shares is outlined in a registration statement filed with the Securities and Exchange Commission. Net proceeds will be used for further development and commercialization of products based on the firm's Coblation low-temperature tissue ablation technology, and for corporate and other general purposes. The Sunnyvale, California firm plans to pursue additional spinal applications within the next year (1"The Gray Sheet" Sept. 13, p. 12). Underwriters BancBoston Robertson Stephens and Bear Stearns have an overallotment option for an additional 150,000 shares
You may also be interested in...
ArthroCare's Entry Into Spine Surgery Market Attracts Backers To Stock
ArthroCare anticipates pursuing additional spinal applications within the next year for its Coblation-based surgical tools following the firm's recent entry into the European spine surgery market.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.